IDH2 and lung carcinoma: Considering that cisplatin is a front-line chemotherapeutic drug of choice for the treatment of lung cancer [7], we analyzed the potential relationship between IDH2 expression and cisplatin sensitivity in lung cancer cells using A549 cell line and its cisplatin-resistant sub-line, A549-CR.